The US Food and Drug Administration (FDA) has authorised a booster dose of the Pfizer Inc (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for those aged 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus, Reuters news agency reported on Thursday.
FDA Acting Commissioner Janet Woodcock stated that this change to the vaccine's emergency use authorisation will allow boosters for groups such as health care workers, teachers and day care staff, grocery workers and those in homeless shelters or prisons.
An outside FDA panel of advisers voted against Pfizer's proposition that boosters were needed by everyone but said that evidence showed they were helpful to older people and those at high risk.
Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg
Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial
Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM
Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
Esperion to acquire Corstasis, expanding cardiovascular portfolio
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
BD receives FDA clearance for Surgiphor 1000mL irrigation system
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
FDA accepts rusfertide NDA and grants priority review for polycythemia vera